Sfoglia per AUTORE
GøRLøV JS
Collezione AOU Città della Salute di Torino
Items : 2
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. in Leukemia / Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.
2022
AOU Alessandria
AOU Città della Salute di Torino
AOU Alessandria
AOU Città della Salute di Torino
Deckert M; Ponzoni M; Pennese E; Cabras G; Thurner L; Smith J; Rummel M; Hertenstein B; Schmoll HJ; Krause SW; Zanni M; Pisani F; Orsucci L; Tucci A; Panse J; Stilgenbauer S; Hess G; Keller U; Balzarotti M; Pukrop T; Gørløv JS; Linton KM; Johnson PW; Hemmaway C; Roth A; Krampera M; Ilariucci F; Fabbri A; Binder M; et alii...
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
2016
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; et alii...